What is Ratio Therapeutics?
Ratio Therapeutics is a specialized biopharmaceutical enterprise dedicated to the advancement of targeted radiopharmaceuticals. The company utilizes a sophisticated platform that integrates proprietary targeting scaffolds, pharmacokinetic modulation, and advanced chelation technologies. By pairing diagnostic imaging with targeted radiotherapy, Ratio Therapeutics enables a theranostic workflow that enhances the precision of cancer treatments. This dual-action methodology allows for the identification of drug candidates while simultaneously delivering therapeutic radioisotopes directly to malignant cells, minimizing systemic toxicity and improving patient outcomes in complex oncology cases.
How much funding has Ratio Therapeutics raised?
Ratio Therapeutics has raised a total of $160M across 4 funding rounds:
Seed
$20M
Series A
$20M
Series B
$50M
Series C
$70M
Seed (2022): $20M, investors not publicly disclosed
Series A (2023): $20M led by Schusterman Family Investments and Duquesne Capital
Series B (2024): $50M supported by Bristol-Myers Squibb
Series C (2026): $70M featuring Lilly, Wasatch Group, Catalio Capital Management, Bristol-Myers Squibb, and Duquesne Family Office
Key Investors in Ratio Therapeutics
Bristol-Myers Squibb
A global biopharmaceutical leader focused on discovering and developing innovative medicines for oncology, immunology, and cardiovascular diseases.
Lilly
A prominent pharmaceutical firm specializing in research-driven innovation across diabetes, oncology, and neuroscience therapeutic areas.
Catalio Capital Management
A specialized investment firm focused on breakthrough biomedical technologies and healthcare innovation across private and public markets.
What's next for Ratio Therapeutics?
With the infusion of $70M, Ratio Therapeutics is well-positioned to transition its lead candidates through critical clinical milestones. The strategic involvement of major industry players suggests a focus on accelerating the commercialization of its theranostic pipeline. Future efforts will likely prioritize the expansion of its internal research capabilities and the strengthening of its clinical research infrastructure. As the company scales, it remains focused on translating its scientific breakthroughs into standardized therapeutic options, aiming to redefine the precision medicine landscape for patients battling aggressive forms of cancer.
See full Ratio Therapeutics company page
